

HALF YEAR RESULTS PRESENTATION SIX MONTHS ENDED 31 DECEMBER 2014

25 FEBRUARY 2015



DISCLAIMER



The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purport to be complete, is given in summary and may change without notice.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. The presentation does not constitute or form part of an offer to buy or sell MVF securities.

This presentation contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors are not all within the control of MVF and cannot be predicted by MVF and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which MVF operate. They also include general economic conditions, exchange rates, interest rates, the regulatory environment, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised.


None of MVF (and their respective officers, employees or agents) (the **Relevant Persons**) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements. The forward looking statements in this presentation reflect views held only at the date of this presentation. Except as required by applicable law or the ASX Listing Rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any forward looking statements, whether as a result of new information or future events. Statements about past performance are not necessarily indicative of future performance.

Certain jurisdictions may restrict the release, publication or distribution of this presentation. Persons in such jurisdictions should observe such restrictions. To the extent permitted by law the Relevant Persons do not accept liability for any use of this presentation, its contents or anything arising in connection thereto including any liability arising from the fault or negligence of the Relevant Persons.

OVERVIEW OF MONASH IVF GROUP



Monash IVF Group (MVG) is a market leader in the fields of fertility care, womens imaging & diagnostics



HALF YEAR HIGHLIGHTS



Underlying Revenue, NPAT and volume growth in 1H FY2015

- Revenues increased \$2.7M (4.7%) to \$60.3M vs pcp including
 - International revenues up 24% vs pcp
 - Monash Ultrasound for Women revenues up 11% vs pcp
- Revenue growth achieved notwithstanding contraction in Assisted Reproductive Services (ARS) volumes in Australian Key Markets which contracted -0.6% versus 4.1% growth assumed in the Prospectus¹
- NPAT increased \$3.4M (45%) to \$11.0M vs pcp
- Overall Group market share marginally increased to 38.1% in Australian Key Markets² (excluding acquisitions)
- New South Wales footprint now established with Next Generation Fertility (Western Sydney), Fertility East (Eastern Suburbs), BUMP IVF (North Shore), Reproductive Medicine Albury & Wagga Wagga
- Overall pregnancy success rates of 33%³, significantly above most recently available industry comparator (ie. VARTA) of 29%
- Strong cash flow management saw Net Debt reduced by \$3.5M after acquisition payments of \$3.2M and IPO expenses of \$3.3M
- Fully Franked interim dividend of 3.25 cents per share declared

Notes:

1. Refer to Monash IVF Group Limited Prospectus, Section 4.7.3.3
2. Based on the combined number of Patient Treatments in Victoria, South Australia, Queensland, Northern Territory and regional market of Albury (New South Wales). Patient Treatments are the sum of fresh and cancelled cycles and frozen embryo transfers.
3. Based on Monash IVF (Victoria and Queensland) and Repromed clinics. "VARTA" comparison based on FY2014 data from Victorian Assisted Reproductive Treatment Authority

HALF YEAR FINANCIAL HIGHLIGHTS



Profit and Loss Analysis

	H1 FY2015 \$M	H1 FY2014 \$M	%
Group revenues	60.3	57.6	4.7%
Operating EBITDA⁽¹⁾	20.3	21.1	-3.8%
<i>Operating EBITDA %</i>	<i>33.7%</i>	<i>36.6%</i>	
Start up and acquisition costs	-1.0	0	N/a
Prior period restructuring costs	0	-2.1	N/a
Group Operating EBITDA ⁽¹⁾	19.3	19.0	1.6%
Depreciation & amortisation	-1.6	-1.4	14.3%
Net Finance expenses	-2.4	-13.6	-82.4%
Profit before Tax	15.3	4.0	282.5%
Income tax (expense) / benefit	-4.3	3.6	-219.4%
Net Profit for the period	11.0	7.6	44.7%
Revenue excluding acquisitions ⁽²⁾	57.3	57.6	-0.3%

(1) These are non IFRS definitions

(2) Excludes Next Generation Fertility and Fertility East

HALF YEAR FINANCIAL HIGHLIGHTS (CONT'D)



Segment Analysis

	H1 FY2015 \$M	H1 FY2014 \$M	%
Revenue			
Australia	57.7	55.5	4.0%
International	2.6	2.1	23.8%
Total	60.3	57.6	4.7%
Operating EBITDA ⁽¹⁾			
Australia	19.2	20.2	-5.0%
International	1.1	0.9	22.2%
Total	20.3	21.1	-3.8%

⁽¹⁾ Operating EBITDA is non IFRS financial information

HALF YEAR FINANCIAL HIGHLIGHTS (CONT'D)




Revenue Variance Analysis

	H1 FY2015 vs H1 FY2014 \$M	% of H1 FY 2014 revenue
Australia		
<i>Revenue excluding acquisitions</i>		
Market growth	-0.3	-0.6%
Market share	0.8	1.4%
Pricing and Mix	-0.1	-0.1%
Other income	-1.2	-2.1%
Total	-0.8	-1.4%
Acquisitions	3.0	5.2%
Total Australia	2.2	3.8%
Total International	0.5	0.9%
Total Group	2.7	4.7%

AUSTRALIAN MARKET MOVEMENT



- Assisted Reproductive Services Patient Treatment growth in Australian Key Markets¹ contracted -0.6%
- Prospectus forecast assumed market growth in Patient Treatments of 4.1% based on historical growth trend
- Prospectus highlighted market growth rate fluctuations occur from time to time²
- Historical growth rates in Australian Key Markets are shown in the adjacent chart, illustrating short term variations occur
(Source: Medicare Benefit Schedule Item Statistics Reports [13200, 13201, 13202 & 13028], Commonwealth Department of Health and Ageing)
- A reversion to normal market growth rates is expected based on long term trends



Notes:

1. Based on the combined number of Patient Treatments in Victoria, South Australia, Queensland, Northern Territory and regional market of Albury (New South Wales)
2. Refer to Monash IVF Group Limited Prospectus, Sections 2.5 and 5.2.10

AUSTRALIAN MARKET SHARE



	H1 2015	H1 2014	%
Number of Patient Treatments in Monash Group's key Australian markets	18,569	18,686	-0.6%
Implied Monash Group market share in Monash group's key Australian markets - Patient Treatments (%)	38.1%	37.8%	+0.8%

- Overall market share in Australian Key Markets¹ (excludes uplift from acquisitions) increased to 38.1% vs 37.8% pcp
- Victorian market share growth offset market share loss in South Australia
 - South Australian market share loss attributable to aggressive pricing by competition, now largely discontinued

Notes:

1. Based on the combined number of Patient Treatments in Victoria, South Australia, Queensland, Northern Territory and regional market of Albury (New South Wales)

PRICING AND TREATMENT MIX



- Frozen Embryo Transfers (FETs) increased to 39.2% of Patient Treatments for the period
- Patient Treatment shift to FETs reflects ongoing change in clinical practice and improvements in FET pregnancy rates
- Preimplantation Genetic Screening/Diagnosis (PGS/D) volumes increased 30% on pcp, The Group now offers world's best technology through "next generation sequencing"
- Average Revenue per Patient Treatment (ARPPT) was stable as price increases and additional PGS/D revenue was negated by the Patient Treatment mix shift

Patient Treatments

	1H FY2015	1H FY2014	Change
Monash Group - Australia			
IVF Cycles	4421	4371	1.1%
Frozen embryo transfers	2833	2415	17.3%
Total Patient Treatments	7254	6786	6.9%
Monash Group – International			
IVF Cycles	295	249	18.5%
Frozen embryo transfers	202	186	8.6%
Total Patient Treatments	497	435	14.3%
Total Monash Group			
IVF Cycles	4716	4620	2.1%
Frozen embryo transfers	3035	2601	16.7%
Total Patient Treatments	7751	7221	7.3%

EXPANDING DOMESTIC FOOTPRINT



Acquisitions & New Locations

- Next Generation Fertility (Western Sydney, NSW) performed to plan for period, delivering 5% of Group Patient Treatments
- Fertility East acquired in December 2014 and accordingly made minimal contribution to H1 FY2015 results
- During the period, new clinic established at Wagga Wagga NSW (“Reproductive Medicine Wagga Wagga”)
- Additional Service Centres (Consulting and Monitoring) established in the Melbourne CBD and Adelaide

Low Intervention Roll Out

- Total low intervention treatments for the period represented 1% of Group Patient Treatments
- BUMP IVF commenced trading in late September 2014 following a delay in opening as detailed in the AGM Update (due to delays in granting of required approvals/licensing). H1 results impacted by three month deferral in opening
- Existing low intervention facilities are expected to trade profitably by the end of 2015
- While early days, no sign of cannibalisation of full service business occurring

INTERNATIONAL – KL FERTILITY



- Revenues increased 24% to \$2.6M
 - Revenue growth underpinned by 14.3% increase in Patient Treatments
- EBITDA increased 22% to \$1.1M
- Continued growth in volumes achieved by additional Fertility Specialists
- Further International opportunities are being reviewed



KL FERTILITY CENTRE
towards parenthood

MONASH ULTRASOUND FOR WOMEN



- Revenues increased 11% vs pcp
- Scans increased 8% vs pcp
- Non Invasive Prenatal Testing (NIPT) increased 115% vs pcp
- MUFW provides a service complementary to our focus on women's health and delivers a diversified income source



FINANCE AND CASH FLOW HIGHLIGHTS



	H1 FY2015 \$M	H1 FY2014 \$M	%
Net operating cash flow	16.8	15.1	11.3%
Purchase of property, plant and equipment ⁽¹⁾	-3.8	-2.2	72.7%
Net interest paid	-3.1	-36.3	-91.5%
Other	0.1	-0.3	133.3%
Free cash flow⁽²⁾	10.0	-23.7	
Payments for issue of share capital ⁽³⁾	-3.3	0.0	N/a
Available cash ⁽²⁾	6.7	-23.7	128.3%
Purchase of business ⁽⁴⁾	-3.2	-5.3	-39.6%
Net increase / decrease in borrowings ⁽⁵⁾	-7.0	23.6	-129.7%
Net cash flow after debt repayment and acquisitions ⁽²⁾	-3.5	-5.4	-35.2%

(1) Property, plant and equipment includes Bump set up costs, new clinic at Wagga Wagga and the rollout of propriety clinical information system

(2) This is a non IFRS financial definition

(3) Payments for issue of share capital relate to IPO costs from June 2014 paid this financial year

(4) Purchase of business refers to Fertility East and deferred consideration on Reproductive Medicine Albury acquisition

(5) H1 FY2015 was voluntary repayment of debt



Banking Facilities and Hedges

- Net Debt \$83.7M (\$87.2M at 30 June 2014)
- Existing debt - total of \$105M facilities available (June 2014 \$105M) drawn to \$89M (June 2014 \$96M) leaving \$16M (June 2014 \$9M) undrawn
- 56.2% of debt hedged with floating to fixed interest swaps (June 2014 52.1%)
- Covenant ratios comfortably met – Leverage Ratio 2.1 (< 3.25) and Interest Cover 8.8 (> 3.00)
- Gearing at 2.1x (based on Net Debt:EBITDA [rolling 12 months])

CAPITAL MANAGEMENT(CONTINUED)



1H FY2015 Dividend

- Fully Franked Interim Dividend of 3.25 cents per share declared
 - Record Date 16 March 2015
 - Payable Date 18 April 2015
- Interim Dividend payout ratio 68% vs Prospectus guidance of 65% of NPAT
- Payout ratio for this period increased given the Group's strong cash flows and an expectation of Patient Treatment growth

FULL YEAR 2015 OUTLOOK



- H2 FY2015 is expected to show an improved financial performance (compared to H1 FY2015) based on the following:
 - Limited market recovery in Patient Treatment numbers in Q4 FY2015 consistent with a return to the longer term trends for the industry and the 4.2% growth in Group New Patient Registrations against the prior year.
 - Improved South Australian performance as local market share rebuilds as indicated by growth in New Patient Registrations. This impact is expected to be stronger in Q4 FY2015
 - Low intervention services gaining momentum following minimal contribution in H1 FY2015
 - Ramp up in volumes from additional Fertility Specialists recruited to the Group in H1 FY2015
 - Fertility East contribution in H2 FY2015
- Based on the above, forecast full year FY 2015 results are as follows:

	Forecast FY 2015 \$ M	Prospectus \$ M	Difference	%
Revenue	123.1	130.4	-7.3	-5.6%
EBITDA	41.3	45.1	-3.8	-8.4%
NPAT	23.7	26.0	-2.3	-8.8%
NPAT - Fertility East acquisition	0.2	-	0.2	N/a
Group NPAT	23.9	26.0	-2.1	-8.1%

- Income tax benefit as highlighted in the October 2014 AGM Update will not reduce the Group's income tax expenses as previously advised, however will reduce cash tax payable by \$2.2M

SUMMARY



- Solid performance in slightly weaker overall ARS market in Australia
- Established NSW clinic footprint through start up and acquisitions
- H1 results impacted by lower than expected Patient Treatment market growth which is expected to return to normal long term growth rate
- Growth in New Patient Registrations indicating recovery commencing in Q4 FY2015
- Fundamental drivers for the industry remain unchanged, despite challenging trading conditions in FY2015
- Forecast long run Patient Treatment growth expected to remain at 4.1% per annum
- Recent acquisitions to be fully integrated over the course of H2 FY2015
- Currently reviewing further acquisition opportunities both domestically and internationally



QUESTIONS